$EVFM something to think about. If an institution is willing to pay 3.65 for a stock that’s trading at 2.85, it would be safe to think that they already got the inside scoop on the sales number, and perhaps even the inside track to new development of the drug. Not trying to pump up this stock or anything, just trying to understand from the business sense of the deal.